Lucas Rut, Villamón Eva, Payá Miguel, Alves Mario, del Olmo Esther, Gozalbo Daniel, Gil M Luisa
Departamento de Farmacología, Universidad de Valencia, Avda V Andrés Estellés s/n, 46100 Burjassot, Valencia, Spain.
FEMS Immunol Med Microbiol. 2004 Apr 9;40(3):239-42. doi: 10.1016/S0928-8244(03)00371-7.
LAAE-14, a lipidic acid-amido ether derivative, has been recently described as a new anti-inflammatory drug. We have studied the effect of treatment with this compound on the susceptibility of mice to in vivo experimental Candida albicans infection. ICR mice orally treated with LAAE-14 (25 mg kg(-1)) and experimentally intravenously infected showed a significantly increased survival as compared to control mice. In vitro, the compound did not inhibit the growth of C. albicans yeast cells or the yeast-to-hyphal transition. The in vitro production of prostaglandin E2 by peritoneal macrophages in response to the yeasts and hyphae of C. albicans was significantly decreased upon treatment with LAAE-14, in a dose-dependent manner. Thus, reduced prostaglandin production during fungal infection could be an important factor in controlling fungal colonisation and infection.
LAAE - 14是一种脂酸酰胺醚衍生物，最近被描述为一种新型抗炎药物。我们研究了用该化合物治疗对小鼠体内实验性白色念珠菌感染易感性的影响。口服LAAE - 14（25毫克/千克）并经实验性静脉感染的ICR小鼠与对照小鼠相比，存活率显著提高。在体外，该化合物不抑制白色念珠菌酵母细胞的生长或酵母向菌丝的转变。用LAAE - 14处理后，腹膜巨噬细胞对白色念珠菌酵母和菌丝体反应产生前列腺素E2的体外产量以剂量依赖的方式显著降低。因此，真菌感染期间前列腺素产生的减少可能是控制真菌定植和感染的一个重要因素。
